Age differentially impacts adaptive immune responses induced by adenoviral versus mRNA vaccines against COVID-19.
Nat Aging
; 4(8): 1121-1136, 2024 Aug.
Article
de En
| MEDLINE
| ID: mdl-38918602
ABSTRACT
Adenoviral and mRNA vaccines encoding the viral spike (S) protein have been deployed globally to contain severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Older individuals are particularly vulnerable to severe infection, probably reflecting age-related changes in the immune system, which can also compromise vaccine efficacy. It is nonetheless unclear to what extent different vaccine platforms are impacted by immunosenescence. Here, we evaluated S protein-specific immune responses elicited by vaccination with two doses of BNT162b2 or ChAdOx1-S and subsequently boosted with a single dose of BNT162b2 or mRNA-1273, comparing age-stratified participants with no evidence of previous infection with SARS-CoV-2. We found that aging profoundly compromised S protein-specific IgG titers and further limited S protein-specific CD4+ and CD8+ T cell immunity as a probable function of progressive erosion of the naive lymphocyte pool in individuals vaccinated initially with BNT162b2. Our results demonstrate that primary vaccination with ChAdOx1-S and subsequent boosting with BNT162b2 or mRNA-1273 promotes sustained immunological memory in older adults and potentially confers optimal protection against coronavirus disease 2019.
Texte intégral:
1
Collection:
01-internacional
Base de données:
MEDLINE
Sujet principal:
Immunité acquise
/
Glycoprotéine de spicule des coronavirus
/
Vaccins contre la COVID-19
/
SARS-CoV-2
/
COVID-19
/
Vaccins à ARNm
/
Vaccin BNT162
/
Vaccin ARNm-1273 contre la COVID-19
Limites:
Adult
/
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Langue:
En
Journal:
Nat Aging
/
Nat. aging
/
Nature aging
Année:
2024
Type de document:
Article
Pays d'affiliation:
Italie
Pays de publication:
États-Unis d'Amérique